Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Capital Expenditures (2016 - 2025)

Protalix BioTherapeutics has reported Capital Expenditures over the past 16 years, most recently at -$866000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$866000.0 for Q4 2025, down 43.62% from a year ago — trailing twelve months through Dec 2025 was $369000.0 (up 45.28% YoY), and the annual figure for FY2025 was $369000.0, up 45.28%.
  • Capital Expenditures for Q4 2025 was -$866000.0 at Protalix BioTherapeutics, down from $498000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for PLX hit a ceiling of $624000.0 in Q2 2024 and a floor of -$917000.0 in Q4 2021.
  • Median Capital Expenditures over the past 5 years was $265500.0 (2021), compared with a mean of $124700.0.
  • Peak annual rise in Capital Expenditures hit 484.85% in 2021, while the deepest fall reached 1355.56% in 2021.
  • Protalix BioTherapeutics' Capital Expenditures stood at -$917000.0 in 2021, then soared by 123.23% to $213000.0 in 2022, then increased by 17.37% to $250000.0 in 2023, then tumbled by 341.2% to -$603000.0 in 2024, then tumbled by 43.62% to -$866000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$866000.0 (Q4 2025), $498000.0 (Q3 2025), and $431000.0 (Q2 2025) per Business Quant data.